APPROACHES TO THE TREATMENT OF METASTATIC BREAST CANCER
DOI:
https://doi.org/10.62480/tjms.2024.vol33.pp46-51Keywords:
Metastatic Breast Cancer, High-Dose Chemotherapy, Metronome TherapyAbstract
Progress in the treatment of this disease, metastatic dissemination is still considered an inclusive condition. In this lecture will be considered questions of «non-standard» therapy, which may be included in our practice in the future
References
Frei E., Antman K., Teicher B. et al. Bone marrow autotransplantation for solid tumors-prospects // Journal of Clinical Oncology. – 1989. – Vol. 7. – № 4. – P. 515–526.
Williams S.F. Is there a role for dose-intensive chemotherapy with stem cell rescue in breast cancer? // Oncology (Williston Park, N.Y.). – 2002. – Vol. 16. – № 12. – P. 1643–1646.
Tartarone A., Romano G., Galasso R. et al. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data // Bone Marrow Transplantation. – 2003. – Vol. 31. – № 7. – P. 525–530.
Gutierrez-Delgado F., Holmberg L.A., Hooper H. et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer // Bone Marrow Transplantation. – 2000. – Vol. 26. – № 1. – P. 51–59.
Gratwohl A., Baldomero H., Rosti G. High-dose chemotherapy for breast cancer // Bone Marrow Transplantation. – 2000. – Vol. 26. – № 6. – P. 599.
Borges V.F., Elias A.D. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 24. – P. 3205–3206.
Ueno N.T., Rondón G., Mirza N.Q. et al. Allogeneic peripheral-blood progenitor-cell transplantation for poorrisk patients with metastatic breast cancer // Journal of Clinical Oncology. – 1998. – Vol. 16. – № 3. – P. 986–993.
Boudin L., Gonçalves A., Sabatier R. et al. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation // Bone Marrow Transplantation. – 2016 – Vol. 51. – № 8 – P. 1082–1086.
Shaked Y., Emmenegger U., Man S. et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity // Blood. – 2005. – Vol. 106. – № 9. – P. 3058–3061.
Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy // Nature Reviews Cancer. – 2004. – Vol. 4. – № 6. – P. 423-436.
Gennari A., Stockler M., Puntoni M. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 16 – P. 2144–2149.
Dirix L.Y., Van Dam P.A., Prove A.M. et al. Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? // Therapeutic Advances in Medical Oncology. – 2010. – Vol. 2. – № 5. – P. 331–342.
Banys-Paluchowski М., Schütz F., Ruckhäberle E. et al. Metronomic Chemotherapy for Metastatic Breast Cancer – A Systematic Review of the Literature // Geburtshilfe Frauenheilkd. – 2016 – Vol. 76. – № 5. – P. 525–534.
Disis M.L., Stanton S.E. Immunotherapy in breast cancer: an introduction // The Breast. – 2017. – Vol. 3. – № 17. – P. 30013–30019.
Katayama H., Boldt C., Ladd J.J. et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis // Cancer Research. – 2015. – Vol. 75. – № 16. – P. 3246–3254.
Gallo S., Sanqiolo D., Carnevale Schianca F. et al. Treating breast cancer with cell-based approaches: an overview // Expert option on biological therapy. – 2017. – Vol. 17. – № 10. – P. 1255–1264.
Hendrickx W., Simeone I., Anjum S. et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis // Oncoimmunology. – 2017. – Vol. 6. – № 2. – e. 253654.
Nanda R., Chow L.Q., Dees E.C. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study // Journal of Clinical Oncology. – 2016. – Vol. 34. – № 21. – P. 2460–2467.
Khosravi-Shahi P., Cabezón-Gutiérrez L., Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies // Asia-Pacific Journal of Clinical Oncology. – 2017. – Vol. 16. – Suppl. 1. [Epub ahead of print].
Borges V.F., Elias A.D. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest // Journal of Clinical Oncology. – 2011. – Vol. 29. – № 24. – P. 3205–3206.
Clifton G.T., Peoples G.E., Mittendorf E.A. The development and use of the E75 (HER2 369-377) peptide vaccine // Future Oncology. – 2016. – Vol. 12. – № 11. – P. 1321–1329.
Gates J.D., Clifton G.T., Benavides L.C. et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide // Vaccine. – 2010. – Vol. 28. – № 47. – P. 7476–7482.
Disis M.L., Pupa S.M., Gralow J.R. et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer // Journal of Clinical Oncology. – 1997. – Vol. 15. – № 11. – P. 3363–3367.
Emens L.A. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade // Expert Review gf Anticancer Therapy. – 2012. – Vol. 12. – № 12. – P. 1597–1611.
Bardia A., Mayer I.A., Diamond J.R. et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients with Metastatic Triple-Negative Breast Cancer // Journal of Clinical Oncology. – 2017. – Vol. 35. – № 19. – P. 2141–2148.
Baselga J., Im S.A., Iwata H. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial // Lancet Oncology. – 2017 – Vol. 18. – № 7. – P. 904–916. А.С. Жабина Т. 18, №3 – 2017 273
Koh M.Y., Spivak-Kroizman T., Venturini S. et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha // Molecular cancer therapeutics. – 2008. – Vol. 7. – № 1. – P. 90–100.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
User Rights
Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).
Rights of Authors
Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.
